“Vaxxinity has broken new ground in the first half of 2023. Now in three independent programs, UB-311, UB-312, and UB-313, we have demonstrated proof of technology and our ability to safely induce antibodies in subjects through active immunization. Importantly, we also demonstrated target engagement of toxic forms of alpha-synuclein, a pathology underlying Parkinson’s disease, with UB-312. This is our first clear proof of mechanism of action in patients, showing that UB-312-induced antibodies clearly bind to the target and slow alpha-synuclein aggregation. We expect this to have positive read-through to our Alzheimer’s and other chronic disease programs. In other words, the platform is doing what we designed it to do,” said Mei Mei Hu, CEO of Vaxxinity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VAXX:
- Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
- Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
- Vaxxinity announces new Phase 1 trial data for UB-312
- Vaxxinity announces Phase 1 Part B trial of UB-312 met primary objectives
